Registry-listed formulations

samidorphan · mesh:C000606131

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

4 source entries across 2 studies. This list may not include all unresolved or historical entries.

  • Samidorphan (Low Dose)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Samidorphan (Medium Dose)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Samidorphan (High Dose)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Samidorphan IVRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)

Phase Distribution

Phase 1
2
67%
Phase 2
1
33%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 12 (66.7%)
Phase 21 (33.3%)

Trials by Status

completed3100%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_2

A Study of ALKS 3831 in Adults With Schizophrenia

NCT01903837
completedphase_1

A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male Volunteers

NCT02504463
completedphase_1

A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users

NCT02218021

Clinical Trials (3)

Showing 3 of 3 trials
NCT01903837Phase 2

A Study of ALKS 3831 in Adults With Schizophrenia

Completed
NCT02504463Phase 1

A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male Volunteers

Completed
NCT02218021Phase 1

A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users

Completed

All 3 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Small molecule
Total Trials
3

External References

ChEMBL
CHEMBL426084

Names & Codes

Research Codes

ALKS 33RDC-0313RDC-0313-00SAMIDORPHAN COMPONENT OF ALKS-5461